Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This observational, multi-center, open-label study will evaluate the prognostic factors of long-term-response and the safety of Pegasys (peginterferon alfa-2a) in patients with HbeAg-negative chronic hepatitis B. Data will be collected for 96 weeks.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients with combined (virological and biochemical) response | 48 weeks after end of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Normalization of serum alanine aminotransferase | 12 months | |
| Safety (Incidence of adverse events) | 12 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with chronic hepatitis B on treatment with Pegasys
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Alexandroupoli | 68100 | Greece | ||||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25368957 | Derived | Goulis I, Karatapanis S, Akriviadis E, Deutsch M, Dalekos GN, Raptopoulou-Gigi M, Mimidis K, Germanidis G, Drakoulis C, Triantos C, Zintzaras E, Bakalos G, Papatheodoridis G. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int. 2015 May;35(5):1540-8. doi: 10.1111/liv.12725. Epub 2014 Nov 20. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Athens |
| 10676 |
| Greece |
| Athens | 115 27 | Greece |
| Athens | 11521 | Greece |
| Athens | 11527 | Greece |
| Athens | 11528 | Greece |
| Athens | 124 61 | Greece |
| Larissa | 41 110 | Greece |
| Pátrai | 265 04 | Greece |
| Piraeus | 18454 | Greece |
| Piraeus | 18536 | Greece |
| Rhodes | 85100 | Greece |
| Thessaloniki | 546 42 | Greece |
| Thessaloniki | 54636 | Greece |
| Thessaloniki | 56429 | Greece |
| Thessaloniki | 57010 | Greece |
| ID | Term |
|---|---|
| D019694 | Hepatitis B, Chronic |
| ID | Term |
|---|---|
| D006509 | Hepatitis B |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D018347 | Hepadnaviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D006525 | Hepatitis, Viral, Human |
| D006521 | Hepatitis, Chronic |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided